Highly elevated sepsis biomarkers in advanced cholangiocarcinoma without sepsis: A case report and literature review DOI Creative Commons

Bianca Karnuth,

Almut Brundert, Claus Langer

и другие.

Medicine, Год журнала: 2025, Номер 104(21), С. e42115 - e42115

Опубликована: Май 23, 2025

Rationale: Inflammatory markers such as C-reactive protein (CRP) and interleukin-6 (IL-6) are often elevated in liver cancer, making it difficult to monitor for bacterial infection. Hence, is tempting use more bacterial-specific sepsis procalcitonin (PCT) during immunosuppressive chemotherapy. This case study highlights the challenges of interpreting clinical chemistry biomarkers patients with advanced cholangiocarcinoma (CCA). Patient concerns: A 55-year-old man presented a mass on routine ultrasonography. MRI CT showed multiple bone metastases. The immunohistochemistry findings were consistent an adenocarcinoma pancreaticobiliary system. After diagnosis primary hepatic CCA (NTM stage IV; FGFR2-SHROOM3 translocation) 14 months chemotherapy, patient developed progressive lesions new lung Diagnoses interventions: During last PCT was highly (>100 ng/mL), usually observed severe or septic shock, whereas CRP moderately (<50 mg/L). had mild leukopenia but no fever, systemic infection shock. Blood urine cultures negative. Outcomes: referral best supportive care, died failure. Retrospective blood analysis revealed high levels soluble CD14 subtype, marker known presepsin. Calcitonin IL-6 above normal, CCA, not PCT/calcitonin-secreting tumor inflammation. Lessons: Oncologists aware that values can be cancer. Here, we further demonstrate elevated, shock-like occur even absence sepsis. In addition, presepsin may although mechanistically unrelated PCT. Therefore, should interpreted caution context, only neuroendocrine hepatocellular carcinoma, which secrete calcitonin, also CCA.

Язык: Английский

Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors DOI Creative Commons
Yoshihisa Takahashi, Erdenetsogt Dungubat,

Hiroyuki Kusano

и другие.

Biomedicines, Год журнала: 2023, Номер 11(10), С. 2761 - 2761

Опубликована: Окт. 12, 2023

Nonalcoholic fatty liver disease (NAFLD) is characterized by excessive fat accumulation in the livers of patients without a history alcohol abuse. It classified as either simple steatosis (nonalcoholic liver) or nonalcoholic steatohepatitis (NASH), which can progress to cirrhosis and hepatocellular carcinoma (HCC). Recently, it was suggested that terms “metabolic dysfunction-associated steatotic (MASLD)” (MASH)” should replace “nonalcoholic (NAFLD)” (NASH)”, respectively, with small changes definitions. MASLD, hepatic manifestation metabolic syndrome, rapidly increasing incidence globally, becoming an increasingly important cause HCC. Steatohepatitic HCC, histological variant its morphological features resembling non-neoplastic closely associated underlying syndrome. Variations genes including patatin-like phospholipase domain-containing protein 3 (PNPLA3), transmembrane 6 superfamily 2 (TM6SF2), membrane-bound O-acyltransferase 7 (MBOAT7) are natural HCC development. The mechanisms development MASLD have not been fully elucidated; however, various factors, lipotoxicity, inflammation, reactive oxygen species, insulin resistance, alterations gut bacterial flora, pathogenesis MASLD-associated Obesity also recognized risk factors for adenomas, recent meta-analyses shown association between intrahepatic cholangiocarcinoma. In this review, we outline pathology tumors.

Язык: Английский

Процитировано

36
Epidemiological characteristics and precise prophylaxis and control of HBV-associated primary liver cancer DOI Open Access

Yuqi Feng,

Letian Fang,

Guangwen Cao

и другие.

Hepatoma Research, Год журнала: 2025, Номер unknown

Опубликована: Янв. 18, 2025

Primary liver cancer (PLC), which includes hepatocellular carcinoma (HCC, 93% in China; 75%-80% worldwide), intrahepatic cholangiocarcinoma (ICC, 4.3% 10%-15% and combined (CHC, 1.6% China), is a global disease that brings heavy burden to the world number of incidence cases on rise. Chronic injury caused by factors such as exposure aflatoxin B1, infection with Clonorchis sinensis, alcohol consumption, chronic hepatitis C virus (HCV), metabolic syndrome are all known risk for PLC. Notably, B (HBV) major factor HCC. Globally, PLC changing from infectious causes factors. Here, we update mechanisms HBV-related HCC (HBV-HCC) development, especially effect HBV evolution development The mutations, viral load, integration, together parameters poor function, key components define highest-risk population HBV-HCC. Antiviral therapy has been proven be effective prevention HBV-HCC population. Non-invasive imaging markers economical convenient screening early Surgical resection transplantation therapeutic options HCC; however, postoperative recurrence reaches 70% five years. Targeted therapy, immunotherapy, radiotherapy can improve survival Active prophylaxes, including vaccination, antiviral treatment, improving lifestyle decrease inflammation, surveillance, cost-effective decreasing

Язык: Английский

Процитировано

1
Highly elevated sepsis biomarkers in advanced cholangiocarcinoma without sepsis: A case report and literature review DOI Creative Commons

Bianca Karnuth,

Almut Brundert, Claus Langer

и другие.

Medicine, Год журнала: 2025, Номер 104(21), С. e42115 - e42115

Опубликована: Май 23, 2025

Rationale: Inflammatory markers such as C-reactive protein (CRP) and interleukin-6 (IL-6) are often elevated in liver cancer, making it difficult to monitor for bacterial infection. Hence, is tempting use more bacterial-specific sepsis procalcitonin (PCT) during immunosuppressive chemotherapy. This case study highlights the challenges of interpreting clinical chemistry biomarkers patients with advanced cholangiocarcinoma (CCA). Patient concerns: A 55-year-old man presented a mass on routine ultrasonography. MRI CT showed multiple bone metastases. The immunohistochemistry findings were consistent an adenocarcinoma pancreaticobiliary system. After diagnosis primary hepatic CCA (NTM stage IV; FGFR2-SHROOM3 translocation) 14 months chemotherapy, patient developed progressive lesions new lung Diagnoses interventions: During last PCT was highly (>100 ng/mL), usually observed severe or septic shock, whereas CRP moderately (<50 mg/L). had mild leukopenia but no fever, systemic infection shock. Blood urine cultures negative. Outcomes: referral best supportive care, died failure. Retrospective blood analysis revealed high levels soluble CD14 subtype, marker known presepsin. Calcitonin IL-6 above normal, CCA, not PCT/calcitonin-secreting tumor inflammation. Lessons: Oncologists aware that values can be cancer. Here, we further demonstrate elevated, shock-like occur even absence sepsis. In addition, presepsin may although mechanistically unrelated PCT. Therefore, should interpreted caution context, only neuroendocrine hepatocellular carcinoma, which secrete calcitonin, also CCA.

Язык: Английский

Процитировано

0